A Study To Evaluate PF-05175157 In Healthy Volunteers
|ClinicalTrials.gov Identifier: NCT01433380|
Recruitment Status : Completed
First Posted : September 13, 2011
Last Update Posted : May 18, 2012
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Drug: PF-05175157 Drug: Placebo||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Phase 1 Study To Evaluate The Effect Of Single Doses Of Pf-05175157 On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
Experimental: 600 mg PF-05175157
Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
Placebo Comparator: Placebo
Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
- Changes in carbohydrate and lipid metabolism [ Time Frame: 24 hours ]
- Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC) [ Time Frame: 24 hours ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01433380
|United States, Louisiana|
|Pfizer Investigational Site|
|Baton Rouge, Louisiana, United States, 70808|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|